Actinium Pharmaceuticals
ATNM
28 hedge funds and large institutions have $16.3M invested in Actinium Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 28 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.28% more ownership
Funds ownership: 0% → 0.28% (+0.28%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.41M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.36M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.33M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.04M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.88M |
Top Sellers
ATNM Hedge Fund Activity: Q2 2014 in Review
28 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q2 2014, worth a combined $16.3M.
Buyers outnumbered sellers: 28 funds opened new ATNM positions and 0 closed out — a net gain of 28 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was BlackRock Fund Advisors, opening a new position worth an estimated $5.41M.
- 28 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q2 2014, up from 0 in Q1 2014.
- Funds reported $16.3M of Actinium Pharmaceuticals stock for Q2 2014.
- 28 funds opened new Actinium Pharmaceuticals positions in Q2 2014 and 0 closed out, a net change of +28 holders.
- The largest Actinium Pharmaceuticals buyer in Q2 2014 was BlackRock Fund Advisors, an estimated $5.41M added.
Based on aggregated 13F filings for Q2 2014.